Esperion Therapeutics Inc.
ESPR
Get informed when a big investor buys or sells
+ FollowMarket Cap$654.91M
Close$
$11.14
252.4% upside
Current Fair Value
252.4% upsideUndervalued by 252.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $654.91 Million |
|---|---|
| Enterprise Value | $794.91 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.11 |
| Beta | 1.07 |
| Outstanding Shares | 251,353,086 |
Return
| Return on Equity | -0.17% |
|---|---|
| Return on Assets | 0.11% |
| Return on Invested Capital | 47.14% |
Valuation & Multiples
| P/E Ratio | -130.17 |
|---|---|
| PEG | 345.1 |
| Price to Sales | 3.16 |
| Price to Book Ratio | -1.58 |
| Enterprise Value to Revenue | 1.9 |
| Enterprise Value to EBIT | 10.4 |
| Enterprise Value to Net Income | 1555 |
| Total Debt to Enterprise | 0.37 |
| Debt to Equity | -0.96 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$106.06 M
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$92.48 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2593▲ 2.94% |
|---|---|
| Total Calls | 3,287,800▼ 21.40% |
| Total Puts | 852,500▼ 11.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.90%▲ 7.56% |
|---|---|
| Total Invested | $478.00M▼ 14.59% |
| Investors Holding | 218▲ 5.00% |
ESG Score
No data
About Esperion Therapeutics Inc.
CEO: Timothy Mayleben